Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 69-77 , January 2012

Rictor-dependent AKT activation and inhibition of urothelial carcinoma by rapamycin

  • Ming-Ju Wu, M.D., Ph.D.

      Affiliations

    • Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Chung-Shan Medical University, Taichung, Taiwan
    • Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
    • Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
    • Corresponding Author InformationCorresponding author. Tel.: +886-4-23592525, ext 3057; fax: +886-4-23594980
    • ,
  • Chi-Hao Chang, M.Sc.

      Affiliations

    • Institute of Biomedical Sciences, National Chung Hsing University, Taichung, Taiwan
    • Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan
    • ,
  • Yung-Tsung Chiu, Ph.D.

      Affiliations

    • Department of Research, Taichung Veterans General Hospital, Taichung, Taiwan
    • ,
  • Mei-Chin Wen, M.D.

      Affiliations

    • Department of Pathology, Taichung Veterans General Hospital, Taichung, Taiwan
    • ,
  • Kuo-Hsiung Shu, M.D.

      Affiliations

    • Division of Nephrology, Taichung Veterans General Hospital, Taichung, Taiwan
    • Chung-Shan Medical University, Taichung, Taiwan
    • ,
  • Jian-Ri Li, M.D.

      Affiliations

    • Division of Urology, Taichung Veterans General Hospital, Taichung, Taiwan
    • ,
  • Kun-Yuan Chiu, M.D.

      Affiliations

    • Division of Urology, Taichung Veterans General Hospital, Taichung, Taiwan
    • ,
  • Yen-Ta Chen, M.C.

      Affiliations

    • Division of Urology, Chang Gung Memorial Hospital, Kaohsiung, Taiwan

Received 11 September 2009 ,Revised 8 November 2009 ,Accepted 10 November 2009.

References 

  1. Vajdic CM , McDonald SP , McCredie MRE , et al.  Cancer incidence before and after kidney transplantation . JAMA . 2006;296:2823–2831
  2. Geissler EK , Schlitt HJ , Thomas G . mTOR, cancer, and transplantation . Am J Transplant . 2008;8:2212–2218
  3. Webster AC , Wong G , Craig JC , et al.  Managing cancer risk and decision making after kidney transplantation . Am J Transplant . 2008;8:2185–2191
  4. Dantal J , Pohanka E . Malignancies in renal transplantation: An unmet medical need . Nephrol Dial Transplant . 2007;22(Suppl 1):i4–i10
  5. Tsang CK , Qi H , Liu LF , et al.  Targeting mammalian target of rapamycin for health and disease . Drug Discov Today . 2007;12:112–114
  6. MacDonald AS . A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts . Transplantation . 2001;71:271–280
  7. Campistol JM , Eris J , Oberbauer R , et al.  Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation . J Am Soc Nephro . 2006;17:581–589
  8. Kauffman HM , Cherikh WS , Cheng Y , et al.  Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies . Transplantation . 2005;80:883–889
  9. Hudes G , Carducci M , Tomczak P , et al.  Temsirolimus, interferon α, or both for advanced renal-cell carcinoma . N Engl J Med . 2007;356:2271–2281
  10. Wu MJ , Lian JD , Yang CR , et al.  High cumulative incidence of urinary tract transitional cell carcinoma after kidney transplantation in Taiwan . Am J Kidney Dis . 2004;43:1091–1097
  11. Hung YM , Chou KJ , Hung SY , et al.  De novo malignancies after kidney transplantation . Urology . 2007;69:1041–1044
  12. Chiang YJ , Wang HH , Liu KL , et al.  Hepatocellular carcinoma following renal transplantation: Experience in northern Taiwan . Transplant Proc . 2008;40:2397–2399
  13. Tian Y , Xiao J , Du LD , et al.  Clinical study of 44 cases of urological malignant tumors following kidney transplantation . Chin J Organ Transplant . 2007;28:417–419
  14. Zhou MS , Zhu YH , Wang LM , et al.  Malignant tumor of urinary system in renal allograft recipients in one center . Chin J Organ Transplant . 2007;28:624–626
  15. Wu MJ . The role of mTOR inhibitors in renal disease . Acta Nephrologica . 2008;22:209–210
  16. Lin J , Tian Y , Tang YW , et al.  Nine cases of conversion from calcineurin inhibitor to sirolimus in the treatment of urological neoplasm in kidney allograft recipients . Chin J Organ Transplant . 2007;28:205–207
  17. Hattori K , Iida K , Joraku A , et al.  Chemopreventive effects of cyclooxygenase-2 inhibitor and epidermal growth factor-receptor kinase inhibitor on rat urinary bladder carcinogenesis . BJU Int . 2006;97:640–643
  18. Wu MJ , Wen MC , Chiu YT , et al.  Rapamycin attenuates unilateral ureteral obstruction-induced renal fibrosis . Kidney Int . 2006;69:2029–2036
  19. Boffa DJ , Luan F , Thomas D , et al.  Rapamycin inhibits the growth and metastatic progression of non-small cell lung cancer . Clin Cancer Res . 2004;10:293–300
  20. Luan FL , Hojo M , Maluccio M , et al.  Rapamycin blocks tumor progression: Unlinking immunosuppression from antitumor efficacy . Transplantation . 2002;73:1565–1572
  21. Pinto-Leite R , Botelho P , Ribeiro E , et al.  Effect of sirolimus on urinary bladder cancer T24 cell line . J Exp Clin Cancer Res . 2009;28:3
  22. Guba M , Breitenbuch PV , Steinbauer M , et al.  Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: Involvement of vascular endothelial growth factor . Nature Med . 2002;8:128–135
  23. Amornphimoltham P , Patel V , Sodhi A , et al.  Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck . Cancer Res . 2005;65:9953–9961
  24. Decker T , Hipp S , Ringshausen I , et al.  Rapamycin-induced G1 arrest in cycling B-CLL cells is associated with reduced expression of cyclin D3, cyclin E, cyclin A, and survivin . Blood . 2003;101:278–285
  25. Di Paolo S , Teutonico A , Leogrande D , et al.  Chronic inhibition of mammalian target of rapamycin signaling down-regulated insulin receptor substrates 1 and 2 and AKT activation: A crossroad between cancer and diabetes? . J Am Soc Nephrol . 2006;17:2236–2244
  26. Breuleux M , Klopfenstein M , Stephan C , et al.  Increased AKT S473 phosphorylation after mTORC1 inhibition is rictor dependent and does not predict tumor cell response to PI3K/mTOR inhibition . Mol Cancer Ther . 2009;8:742–753
  27. O'Reilly KE , Rojo F , She QB , et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates AKT . Cancer Res . 2006;66:1500–1508
  28. Sun SY , Rosenberg LM , Wang X , et al.  Activation of AKT and eIF4E survival pathways by rapamycin-mediated mammalian target of rapamycin inhibition . Cancer Res . 2005;65:7052–7058
  29. Zhang H , Bajraszewski N , Wu E , et al.  PDGFRs are critical for PI3K/AKT activation and negatively regulated by mTOR . J Clin Invest . 2007;117:730–738
  30. Sarbassov DD , Ali SM , Sengupta S , et al.  Prolonged rapamycin treatment inhibits mTORC2 assembly and ATK/PKB . Mol Cell . 2006;22:159–168
  31. Abraham R , Gibbons JJ . The mammalian target of rapamycin signaling pathway: Twists and turns in the road to cancer therapy . Clin Cancer Res . 2007;13:3109–3114
  32. Wan X , Harkavy B , Shen N , et al.  Rapamycin induces feedback activation of AKT signaling through an IGF-1R-dependent mechanism . Oncogene . 2007;26:1932–1940
  33. Fan QW , Knight ZA , Goldenberg DD , et al.  A dual PI3 Kinase/mTOR inhibitor reveals emergent efficacy in glioma . Cancer Cell . 2006;9:341–349

PII: S1078-1439(09)00362-7

doi: 10.1016/j.urolonc.2009.11.009

Urologic Oncology: Seminars and Original Investigations
Volume 30, Issue 1 , Pages 69-77 , January 2012

Article Tools

* Image Usage & Resolution